News – Global Alzheimer’s Platform Foundation

News

Learn more about the latest in Alzeimer's disease research, including the Global Alzheimer's Platform Foundation’s® impact on Alzheimer's and clinical trials.
Filter through our news categories
Press Releases

Global Alzheimer’s Platform Foundation Statement on Biogen’s Submission of Aducanumab Application to the FDA

July 9, 2020
Washington D.C. (July 9, 2020) – The President of the Global Alzheimer’s Platform Foundation (GAP), John Dwyer, issued the following statement regarding Biogen’s submission of its BLA application for Aducanumab with the FDA: “The Alzheimer's research community is looking forward to a thoughtful review of Aducanumab and ideally, approval by the FDA. This application represents a singular accomplishment of Biogen and the broader research community. Most importantly, it is a testament to...
In the News

How Alzheimer’s Clinical Trials Have Become COVID-19 Victims

GAP President, John Dwyer, and GAP-Net site Great Lakes Clinical Trial spoke on the hit Alzheimer's clinical trials have taken since COVID-19, and the losses that will come of it. After a frustrating 2019, Alzheimer’s researchers had reason to look forward to 2020 as a year of promise. Then the pandemic struck. “Last year, seven [Alzheimer’s clinical] trials were stopped. The portfolio was more than halved,” said John R. Dwyer,...
Featured

Alzheimer’s Research Needs Your Help

July 2, 2020
Alice Bailey, a GAP Citizen Scientist Award nominee, wrote an Op-Ed piece in the Cambridge Chronicle about her experience as an Alzheimer's patient and clinical trial volunteer. For many seniors, Alzheimer’s disease is surrounded by fear. Fear of the diagnosis can be so strong that some don’t want to learn about or talk about the disease. And it is scary -- before COVID-19, Alzheimer’s was in the top-10 causes of...
Featured

Alzheimer’s Researchers Fight Delays Caused by COVID-19

June 29, 2020
GAP President John Dwyer and GAP-Net Site Roper St. Francis Healthcare Research and Innovation Center in Charleston, South Carolina were featured on LIVE 5 WCSC News about the need for Alzheimer's clinical trials to begin again. CHARLESTON, S.C. (WCSC) - Medical experts are worried that the COVID-19 pandemic has put delays on the search for a cure for Alzheimer's. John Dwyer is the president of the Global Alzheimer’s Platform Foundation,...
Featured

In the Wake of COVID-19: Trials Interrupted, Delayed, Cancelled

June 24, 2020
GAP President John Dwyer was quoted in AlzForum about the challenges and changes in Alzheimer's clinical trials due to COVID-19. As Alzheimer’s research comes to, scientists are taking stock of the damage. In the academic world, the main cost was time (see Part 1 of this story). For most clinical studies, the damage was more tangible, with at least a brief interruption in dosing, and a complete halt of recruitment. Larger trials...
In the News

Critical Medical Research Put on Hold Amid Pandemic

GAP-Net Site, Brigham and Women's Center for Alzheimer's Research and Treatment, and GAP President, John Dwyer, were featured on Boston 25 News talking about how Alzheimer's Clinical Trial volunteers and researchers are getting back on track after COVID-19 setbacks. The pandemic has put a pause on critical medical research. At Brigham and Women's Hospital, some health care workers involved with a clinical trial for Alzheimer's were called to help care...
In the News

Clinical Trials Press Forward in Age of COVID

June 16, 2020
GAP-Net site Great Lakes Clinical Trials in Chicago was featured in the Chicago Sun Times, where they discussed the difficulties of attracting Alzheimer's disease trial participants during COVID-19. Jim Butler is receiving his monthly 45-minute infusion of drugs. What kind of drugs? He doesn’t know. Nor do the nurses administering them. Could be an experimental medicine that will help his brain fight Alzheimer’s disease. Or could be a placebo that...
In the News

Improv Improves How Caregivers Work with Patients

In February, Stomping Ground Comedy Theater lead a workshop for caregivers about how to best interact with loved ones living with Alzheimer's disease or dementia. They also attended our 2020 GAP-Net Site Optimization Conference at the end of February. Above Photo: Lindsey Goldsapp of Stomping Ground Comedy Theater leads a workshop for caregivers at the Preston of the Park Cities. (Jennifer Trotter / Global Alzheimer's Platform Foundation) About 20 strangers...
Featured

GAP Statement on Racial Inequality

June 2, 2020
June 2, 2020 The events that spurred the reaction around the country this weekend are painful reminders that injustice remains in our world. At the Global Alzheimer’s Platform Foundation® (GAP), we agree that monumental changes on local and national levels are necessary to address the issues plaguing Black and African American people in our country today. As we work with our GAP-Net sites, sponsors, funders and friends, we strive to...
In the News

Guest Column: Another Growing Health Crisis

May 27, 2020
This editorial was run in the Kelowna Daily Courier on May 20, 2020, on Clinical Trials Day during Clinical Trial Awareness Week. Dr. Kim Christie is the President of GAP-Net Site Okanagan Clinical Trials in Kelowna, British Columbia in Canada. Today is Clinical Trials Day, an observance commemorating the first controlled clinical trial conducted by James Lind on May 20, 1747. Much has changed since Lind studied scurvy in sailors,...
Uncategorized

KU Alzheimer’s Disease Center Team Earns Diversity, Equity and Inclusion Award

May 22, 2020
GAP-Net Site, the University of Kansas Alzheimer's Disease Center's (KU ADC) Outreach, Recruitment and Education Core earned the 2020 University of Kansas Medical Center Diversity, Equity and Inclusion Award. The University of Kansas Alzheimer's Disease Center's Outreach, Recruitment and Education Core earned the 2020 University of Kansas Medical Center Diversity, Equity and Inclusion Award. Presented by the KU Medical Center Office of Diversity, Equity and Inclusion, the annual honor highlights the significant...
In the News

Results of GERAS-US Study Demonstrate Societal Cost Burden for Patients and Caregivers During Early Stages of Alzheimer’s Disease

May 21, 2020
Dorene M. Rentz, PsyD, from GAP-Net site Brigham and Women's Center for Alzheimer's Research and Treatment, and Professor of Neurology at Harvard Medical School co-authored Costs of Early Stage Alzheimer’s Disease in the United States: Cross-Sectional Analysis of a Prospective Cohort Study (GERAS-US)1. You can find the study posted in The Journal of Alzheimer's Disease on May 19, 2020. INDIANAPOLIS, May 19, 2020 /PRNewswire/ --Eli Lilly and Company (NYSE: LLY) announced baseline results...
In the News

Coronavirus Takes its Toll on Alzheimer’s Clinical Trials

April 3, 2020
Global Alzheimer's Platform Foundation president, John Dwyer, was quoted on how GAP is supporting GAP-Net sites during the COVID-19 pandemic, emphasizing the importance of safety and remote clinical trial testing. The coronavirus pandemic is upending not only life as we knew it, but Alzheimer’s clinical studies as well. In the United States, Europe, and Australia, most sites have put observational cohort studies on hold, and many have stopped dosing and...
In the News

When a Drug Study Abruptly Ends, Volunteers Are Left to Cope

March 5, 2020
A participant might commit months or years to a drug trial, only to see it vanish overnight. John Poritsky was enrolled in a clinical trial for a drug to treat early Alzheimer’s disease. But the trial was canceled abruptly and publicly, before researchers gave him notice.Credit...Michelle Gustafson for The New York Times On March 21, 2019, the staff at the Penn Memory Center in Philadelphia was scrambling to learn more...
In the News

Researchers Struggling to Find Alzheimer’s Clinical Trial Participants

A site in the Global Alzheimer's Platform Foundation's network, ClinCloud Clinical Research, was featured on FOX35 Orlando on March 4, 2020 at 6pm. Click here to watch the segment. MAITLAND, Fla. - Researchers have been spending years trying to cure Alzheimer's Disease. We've seen several medical breakthroughs in Central Florida, but they are still running into problems. They have answers and tests, but no one to try them.  There is so much fear...
In the News

Alzheimer’s Studies in Central Florida Need More African Americans

March 3, 2020
This past week, the Global Alzheimer’s Platform Foundation, which works with a national network of clinical research centers, held its annual Site Optimization Conference in Orlando. The conference brings together the leaders of more than 80 clinical trial sites throughout the U.S. and Canada who work day in and day out to identify a cure for Alzheimer’s disease.  More than 580,000 Floridians have Alzheimer’s disease, a progressive brain condition for...
In the News

Hispanics to Volunteer in Alzheimer’s Studies

February 27, 2020
A Spanish translation of the article below can be found on Orlando Sentenial posted on February 27, 2020 by Ginayra Alvarado Villegas. According to statistics from the Alzheimer’s Association in the United States, every 65 seconds a person develops Alzheimer’s disease, a disease that has doctors and researchers conducting studies to develop a drug or treatments that combat this type of dementia that develops mainly in older people.  The disease...
In the News

Early-Onset Dementia and Alzheimer’s Diagnoses Spiked 373 Percent for Generation X and Millennials

CHICAGO, Feb. 27, 2020 /PRNewswire/ -- The number of commercially insured Americans age 30 to 64 diagnosed with early-onset dementia or Alzheimer's disease increased by 200% from 2013 to 2017. The average age of a person living with either form of dementia is 49. The findings came from a new Blue Cross Blue Shield Association (BCBSA) report, "Early-Onset Dementia and Alzheimer's Rates Grow for Younger Americans," part of the Blue Cross Blue Shield,...
Press Releases

Investors Meet Opportunity at Inaugural Global Alzheimer’s Platform Foundation Innovation Summit

February 26, 2020
At a pivotal time in Alzheimer’s research, the GAP Foundation and the Alzheimer’s Drug Discovery Foundation will connect funders with leading innovators Updated on March 26, 2020: The Global Alzheimer's Platform Foundation (GAP) has announced it is postponing the GAP Innovation Summit that was to be held on May 5, 2020 with our partner, the Alzheimer's Drug Discovery Foundation (ADDF). GAP and ADDF reiterates that the health, well-being and safety...
Blog

A Meeting of the Minds

February 14, 2020
For the first time in 15 years, there are new Alzheimer’s drug treatments on the horizon that are expected to seek regulatory approval by the FDA and leading experts are increasely optimistic that a major breakthrough in Alzheimer’s research will occur within the next five years. We are at a moment of peak opportunity – and there is a pressing need – to connect innovators, funders, and investors to continue...
In the News

Georgetown’s Alzheimer’s Clinic Marks 20 Years, but Hopes Research can Make it Obsolete.

January 17, 2020
The Global Alzheimer's Platform Foundation recognizes the impact that GAP-Net site Georgetown University Medical Center's Memory Disorders Program has had on Alzheimer's disease research. We congratulate them on their 20 years of dedication and service to the field. WASHINGTON (WJLA) — It's estimated that one in 10 people 65 and over has Alzheimer's disease. That's nearly 6 million Americans. There is promising research on the horizon, though, thanks in part to...
In the News

Rhode Island’s Man of the Year for 2019

January 3, 2020
The Global Alzheimer's Platform Foundation is proud and honored to work with GAP Net site Butler Hospital Memory and Aging Program's Dr. Stephen Salloway, who was named Rhode Island's Man of the Year for 2019. It is the cruelest of diseases. It is the sixth leading cause of death in America.  In the United States, an estimated 5.8 million Americans have been diagnosed with Alzheimer’s disease. Statisticians predict that in the next...
Blog

The Invaluable Role of Caregivers

November 19, 2019
It’s fitting that November is National Alzheimer’s Disease Awareness Month and National Family Caregivers Month. Nearly half of all caregivers for older adults in the United States - family, friends and other unpaid caregivers – are caring for someone with Alzheimer’s disease (AD).   Caregivers are essential to those living with Alzheimer’s and contribute 18.5 billion hours of care valued at nearly $234 billion. Caregivers for people with Alzheimer’s dementia...
Blog

Focus on the Funding

October 31, 2019
The facts are staggering… every 65 seconds someone in the United States develops Alzheimer’s disease. It is the most expensive disease in America, with the total direct cost of treatment approaching $300 billion annually - greater than for cancer or heart disease. It is the only leading cause of death in the US that cannot be prevented, cured or even slowed. Yet funding to fuel the research and trials needed...
Press Releases

Citizen Scientists Move Researchers Closer to Alzheimer’s Cure

October 23, 2019
Three research volunteers given first ever national award for their essential role in combatting the greatest public health crisis for our society in this century Washington, DC (October 23, 2019) –  Today, the Global Alzheimer’s Platform Foundation® (GAP) honors three Citizen Scientists® in recognition of the indispensable role clinical trial volunteers play in the fight against Alzheimer’s disease. Alzheimer’s is a national public health crisis, with more than 5.8 million...
Press Releases

Global Alzheimer’s Platform Foundation Commends Biogen and Eisai On Positive Aducanumab Findings

October 22, 2019
First disease-modifying drug in 16 years to be submitted for FDA approval in 2020 ***John Dwyer is available for comment today live from the National Alzheimer's Summit in Washington, D.C.***  Washington, DC (October 22, 2019) – The President of the Global Alzheimer’s Platform Foundation (GAP), John Dwyer, issued the following statement on the announcement today by Biogen and Eisai that a new analysis of a larger dataset from clinical studies...
Blog

Determined to End Alzheimer’s Disease: A Global Epidemic

October 1, 2019
The fight against a global epidemic September is a key month in the fight against Alzheimer’s and other dementias. Driven by Alzheimer’s Disease International, September has been designated as World Alzheimer's Month with World Alzheimer's Day on September 21 to prompt organizations worldwide to raise awareness and challenge the stigma that surround dementia. Global efforts are vital as people of varying races and ethnicities have different levels of risk. These worldwide...
In the News

Sharpton Blends Civil Rights Struggle with Disparaging Access to Health Care

September 26, 2019
Al Sharpton delivered the keynote address for the Black Health Care Coalition, speaking out against the health care of black people and specifically Alzheimer’s. Turning his attention to the upcoming 2020 election, Sharpton says “All of the candidates running for President of the United States have health plans and should be focusing to eliminate the disparity that causes minorities to face more challenges. There is more we can do in...
In the News

Alzheimer’s Impact is a Societal and Economic Issue, Health Advocate says

September 20, 2019
George Vradenburg is the head of UsAgainstAlzheimer's, which works to bring the disease to the forefront of government leadership to fund prevention and an eventual cure. CLEVELAND, Ohio -- Alzheimer’s disease afflicts nearly 6 million people in the United States, and sadly affects the many more millions of people who love them. Yet the chairman and co-founder of UsAgainstAlzheimer’s believes that most people -- especially those who could help make...
Press Releases

Spartan Bioscience Partners with the Global Alzheimer’s Platform Foundation to Accelerate Alzheimer’s Research

July 31, 2019
Spartan will donate $5 to the GAP Transportation Program from each sale of its rapid APOE test to GAP-Net Research Sites Ottawa, Canada (July 31, 2019) – Spartan Bioscience today announced a partnership with the Global Alzheimer’s Platform Foundation® (GAP) to help recruit possible study participants and accelerate Alzheimer’s clinical trials. Through the partnership, Spartan will donate $5 from each sale of its rapid Apolipoprotein E (APOE) genetic pre-screening test to the GAP Transportation...
In the News

Volunteers Needed for Northeast Ohio Alzheimer’s Disease Clinical Trials

July 22, 2019
CLEVELAND, Ohio -- The long quest to find a cure for Alzheimer’s disease could become discouraging. But ordinary people won’t allow that. They are a source of encouragement for doctors and researchers dedicated to stifling the disease, and for the people stricken by it. “Participating in a clinical trial gives me and others the opportunity to do for those who are after us what others did for us in past...
In the News

Two RSF Research and Innovation Center Patients Honored as Citizen Scientist Award Nominees

July 10, 2019
Two RSF Research and Innovation Center patients have been honored as nominees for the Citizen Scientist Award celebrating Alzheimer’s disease clinical trial participants. Wayne Vereen and Sharon Fratepietro have been clinical trial volunteer patients at the RSF Research and Innovation Center for more than four years, and during that time, they’ve received monthly infusions on site. Researchers rely on volunteers to help find a cure. Dr. Jacobo Mintzer and his research...
In the News

Advocate Recognizes Alzheimer’s Patients, Care Partners

June 25, 2019
With support from the nonprofit Global Alzheimer's Platform Foundation, Advocate Lutheran General Hospital and Advocate Research Institute recently honored patients with Alzheimer's disease and their care partners who have participated in Alzheimer's disease research at the Advocate Memory Center. This local ceremony is part of the inaugural Citizen Scientist Awards® Program, the first national awards program honoring Alzheimer's disease clinical trial participants. More than 5.7 million Americans suffer from Alzheimer's...
In the News

Alzheimer’s Patients Saluted for Dedication to Drug Trials

June 20, 2019
GAP-Net site Okanagan Clinical Trials in Kelowna, BC recognized three of its Citizen Scientist Awards nominees in a ceremony at the Okanagan Innovation Centre in downtown Kelowna. A dozen times over two years, Gary Millward and his wife, Debra, drove from Quesnel to Kelowna through everything from wildfires and winter storms to rain and brilliant sunshine. The couple was in search of a drug that would slow the brain degeneration...
Press Releases

Global Alzheimer’s Platform Foundation Honors More Than 100 Clinical Trial Participants During National Citizen Scientist Week.

June 17, 2019
During National Citizen Scientist Week, June 17-21, GAP Honors More Than 100 Award Nominees Washington, DC (June 17, 2019) – June 17-21, 2019 is the first ever National Citizen Scientist Week, a time to honor people who volunteer for Alzheimer’s research and inspire hope for new therapies for the disease. To celebrate the contributions of the remarkable volunteers who are participating in Alzheimer’s clinical trials, the Global Alzheimer’s Platform Foundation (GAP) is recognizing more than 100...
In the News

Alzheimer’s Disease: Risk Factors, Treatments and More

June 13, 2019
A podcast discussing Alzheimer’s disease – research, risk prevention, and other related topics. Robert Herriman is joined by Phil Sabel, M.A., the Clinical Research Coordinator at GAP-Net site Axiom Clinical Research in Tampa. Click here to listen to the June 13, 2019 episode.
In the News

Is an Alzheimer’s Cure on the Horizon?

June 1, 2019
By the time I was old enough to ask my grandmother questions about her life, it was too late. All I had were skeletons of stories I heard from my mom. I knew that it had been difficult for my grandmother when her parents, Irish immigrants on the vaudeville circuit, left her behind to help care for her younger brother when they traveled. But who cared for her? I heard...
In the News

8 Ways to Reduce Your Risk of Alzheimer’s (and Maybe Help Researchers Find a Cure Faster)

May 26, 2019
The threat of Alzheimer’s disease looms over an aging America, but could a cure be in the offing? And if so, how soon? Experts say the answer is “yes” — and by the year 2025. That’s the date they’re shooting for, anyway. Much as President Kennedy once vowed to send a man to the moon by the year 1970, the federal government now is putting billions of dollars behind a...
Press Releases

Global Alzheimer’s Platform Foundation Commends National Institute on Aging for Advancing Its 2025 Goal by Funding a Diversified Portfolio of Studies

May 20, 2019
NIA Makes $9 Million Multiyear Grant to Study New Therapeutic Approach, an Orally- Administered Treatment for Alzheimer’s Washington, DC (May 20, 2019) – The President of the Global Alzheimer’s Platform Foundation (GAP), John Dwyer, today issued the following statement: “The nearly six million Americans with Alzheimer’s and their families deserve for no scientific stone to go unturned in the search for a cure. The Global Alzheimer’s Platform Foundation commends the National...
In the News

Dr. Anna Burke Named 2019 Healthcare Innovator of the Year

May 3, 2019
AzBusiness recognized Dr. Anna Burke as its 2019 Healthcare Innovator of the Year for her work in treating the behavioral and psychiatric disturbances that result from Alzheimer’s disease as well as her work building a community outreach program in the Phoenix area to teach people about brain health, Alzheimer’s, and clinical research. Dr. Burke is a geriatric psychiatrist and director of neuropsychiatry at GAP-Net site Barrow Neurological Institute in Phoenix....
In the News

When It Comes to Alzheimer’s, Important Changes Are Coming for MA Beneficiaries

April 19, 2019
The majority of experts agree that because Alzheimer’s disease is significantly underdiagnosed and underreported, a large number of people may not know they have it.  We have both spoken at length about the importance of early detection and diagnosis to allow for earlier interventions and care planning along with a broad array of methods and pathways: pharmacological research and development, increased clinical trials, participation in longitudinal studies, proactive brain health...
Press Releases

Global Alzheimer’s Platform Foundation Commends Commissioner Seema Verma and CMS for New Medicare Advantage Benefits and Payment Policies That Will Improve the Care Of Beneficiaries At Risk For Alzheimer’s and Related Dementias

April 10, 2019
Washington, DC (April 10, 2019) – The President of the Global Alzheimer’s Platform Foundation (GAP), John Dwyer, today issued the following statement: “The Global Alzheimer’s Platform Foundation thanks Commissioner Seema Verma and the Centers for Medicare and Medicaid Services (CMS) for its thoughtful and impactful leadership in implementing policies that will improve Medicare Advantage beneficiaries’ ability to maintain their memory fitness by expanding supplemental benefits programs that will support memory fitness...
In the News

Alzheimer’s Disease Trials: Where Do We Go From Here?

April 9, 2019
The Alzheimer’s disease space is not an easy one for pharma companies to navigate. In 2018 alone, Lundbeck, Takeda, Merck, Janssen, AstraZeneca, and Eli Lilly and Company all faced setbacks or poor trial results. In March 2019, we learned that Biogen and Eisai also terminated late-phase studies. Fortune magazine notes few spaces in the life sciences have fathered failure to the extent that experimental Alzheimer’s drugs have.   The Global...
In the News

In Year Three, GAP Trial Network Is Starting to Hum

March 21, 2019
Outside the daffodils and forsythia were blooming, but the group assembled in Nashville, Tennessee, hardly took notice. At the GAP-Net Site Optimization Conference, held February 27–March 1, representatives of 61 academic and private clinical trial sites had eyes and minds trained on efforts aiming to improve how Alzheimer’s disease clinical trials are done—and after years of prep work, some of those efforts are starting to blossom. The changes come as...
In the News

Addressing the GAPs in Alzheimer’s Trials, Treatment

March 12, 2019
The Global Alzheimer's Platform (GAP) Foundation, an organization dedicated to improving Alzheimer's clinical trials in the quest of a cure, has just wrapped the GAP-NET Site Optimization Conference in Nashville. The Feb. 27-March 1 meeting brought together approximately 150 representatives from its network of Alzheimer's clinical research sites. The third annual GAP-NET conference attracted the range of professionals required to successfully plan and launch Alzheimer's clinical trials including major researchers,...
In the News

Boosting Alzheimer’s trial participation via Medicare Advantage “memory fitness programs”

March 11, 2019
Clinical trials represent future hope for patients seeking better care, and there is no disease more in need of better care than Alzheimer’s disease. While death rates among most cancers, as well as heart disease, HIV-related illness, and other categories, have declined in the past decade, there has been no progress for Alzheimer’s disease. Better health and wellness overall may be having a beneficial effect that has produced a reduction...
Press Releases

GAP Foundation Unveils Roadmap for Increasing Participation in Alzheimer’s Research

February 28, 2019
GAP President Calls Memory Fitness Programs Through Medicare Advantage “a Game-Changer” Nashville (February 28, 2019)? – Global Alzheimer’s Platform Foundation (GAP) President John Dwyer today announced a roadmap for increasing participation in Alzheimer’s clinical trials by supporting and collaborating with memory fitness supplemental benefit programs offered through select Medicare Advantage plans across the United States. Dwyer made the announcement in a speech to more than 150 experts on Alzheimer’s clinical trials...
Press Releases

Leading Alzheimer’s Researchers Coming to Nashville for GAP-Net Site Optimization Conference

February 27, 2019
Researchers, recruiters, and CEOs from more than 70 Alzheimer’s clinical trial sites to share strategies on finding a cure for the deadly disease From February 27 – March 1, the Global Alzheimer’s Platform Foundation (GAP), an organization dedicated to speeding and improving Alzheimer’s clinical trials in pursuit of a cure, will convene more than 150 representatives from its network (GAP?Net) of 70+ Alzheimer’s clinical research sites at the Nashville Marriott at Vanderbilt...
In the News

A Cure for Alzheimer’s is Not Possible Without You

February 26, 2019
There are many open, important clinical trials in Tennessee right now targeting Alzheimer’s disease and related conditions. It’s been 18 months since Nashville legend Glen Campbell died after a long battle with Alzheimer’s disease. Glen and his family bravely shared his heartbreaking journey in the hope of inspiring better care and research for the disease, for which there is no known cure. Glen even sang about it: “I'm never gonna...
Press Releases

Barrow Receives $100,000 Grant for Alzheimer’s Program

February 19, 2019
Global Alzheimer’s Platform Foundation recognizes strong, expanding research WASHINGTON, DC (February 19, 2019) - The Global Alzheimer's Platform Foundation (GAP) announced a $100,000 grant to the Barrow Neurological Foundation to optimize and support the Alzheimer’s clinical trials program at Barrow Neurological Institute at Dignity Health St. Joseph’s Hospital and Medical Center. The grant will go toward participant retention efforts, staff education programs, improving productivity and building a database for clinical trial recruitment. “Barrow Neurological Institute is...
Press Releases

$90,000 GAP Grant to Toronto Memory Program Funds Alzheimer’s Education & Outreach

January 22, 2019
Grant Funds January 28 Community Event at Ontario Science Centre and Expanded Clinical Trial Education Programs TORONTO – January 22, 2019 ---The Global Alzheimer’s Platform Foundation and Toronto Memory Program have initiated a multi-faceted project to educate the Ontario community about Alzheimer’s disease, brain health and the role of Alzheimer’s clinical trials. Toronto Memory Program is a member of the GAP-Net network of 70 prominent research sites working with the nonprofit Global Alzheimer’s Platform Foundation to speed and improve...
Press Releases

Chicago Event to Encourage Participation in Alzheimer’s Clinical Research

November 2, 2018
Event is on November 8, Chicago Alzheimer’s Awareness Day On November 8th - Chicago Alzheimer's Awareness Day - Great Lakes Clinical Trials and the Global Alzheimer's Platform Foundation are hosting a major community event for people in the community who are interested in learning more about memory concerns and Alzheimer's disease. Research volunteers, including care partners, are being honored and celebrated, and will share their personal stories and motivation for volunteering. People from the community will...
Press Releases

Statement from Global Alzheimer’s Platform (GAP) Foundation on the National Strategy for Recruitment and Participation in Alzheimer’s Disease Clinical Research

October 19, 2018
WASHINGTON, D.C. – “I would like to thank the National Institute on Aging for its thoughtful work on the national strategy. More effective recruitment means faster trials and getting approved therapies to market years sooner. The Global Alzheimer’s Platform Foundation is pleased to join in this effort by building a better research infrastructure through GAP-NET, its network of leading academic and private research centers; forging partnerships with healthcare professionals to increase...
Press Releases

Global Alzheimer’s Platform Foundation Launches Citizen Scientist Awards®, A National Initiative Celebrating Clinical Trial Participants

September 25, 2018
Winners to be recognized at UsAgainstAlzheimer’s 2019 National Summit in Washington, D.C. WASHINGTON, D.C. (September 25, 2018) – More than 5.7 million Americans suffer from Alzheimer’s disease and researchers rely upon clinical trial volunteers to be the first step towards a cure. The Global Alzheimer’s Platform Foundation (GAP) has launched the Citizen Scientist Awards®, the first national awards program recognizing and celebrating Alzheimer’s disease clinical trial participants. The awards are designed to broaden awareness of the benefits of clinical research for...
In the News

Top Alzheimer’s Researchers Hope That Near-100 Dementia Drugs in Trials Are Moving Closer to a Breakthrough

June 22, 2018
Top Alzheimer’s Researchers Hope That Near-100 Dementia Drugs in Trials Are Moving Closer to a Breakthrough The search for a drug to treat Alzheimer’s disease, the most common form of dementia, has been marked by clinical trial failures.A new report from top researchers says the number of drugs advancing through clinical phase two and phase three trials provides reason to believe that breakthroughs may be in the current pharmaceutical pipeline.The...
In the News

How a Raleigh Clinic is Helping Alzheimer’s Patients

April 13, 2018
Alzheimer’s clinical trial participants are getting a lift to their appointments at Raleigh Neurology Associates. The Global Alzheimer’s Platform Foundation, in partnership with Lyft, is providing transportation to participants in an Eli Lilly study testing a therapy to attack plaque in the brain characteristic of Alzheimer’s disease. Sean Walsh, director of clinical research at Raleigh Neurology Associates, says the new partnership will help the patient experience and increase efficiency and lower costs. Raleigh Neurology is one of 15...
Press Releases

Global Alzheimer’s Platform (GAP) Foundation Launches Partnership with Lyft to Transport Clinical Trial Participants to and from Clinical Research Facilities Across North America

March 20, 2018
Lyft drivers will transport clinical trial participants to and from GAP-Net research sites WASHINGTON, D.C. (Mar. 20, 2018) – The Global Alzheimer’s Platform Foundation has launched a partnership with Lyft to provide transportation for Alzheimer’s clinical trial participants to and from research sites. The partnership began on Feb. 20 with a pilot in California. Transportation will be available for participants and care partners who are part of Eli Lilly and Company’s (Lilly) study TRAILBLAZER-ALZ, an Alzheimer’s disease clinical trial testing...
Press Releases

Statement from Global Alzheimer’s Platform (GAP) Foundation in Response to Bill Gates’ Investment in Alzheimer’s Research

November 13, 2017
WASHINGTON, D.C. – “The Global Alzheimer’s Platform Foundation (GAP) enthusiastically welcomes Bill Gates and his team to the fight against Alzheimer’s disease. This epidemic, which affects millions of people worldwide, is growing exponentially and requires new thinking and investment to begin to stem that tide. We at Global Alzheimer’s Platform Foundation are focused on disrupting the Alzheimer’s clinical trial system by collaborating with our 59 (and growing) GAP-Net research sites to reduce time-to-trial by...
In the News

Can GAP double the number of patients in Alzheimer’s trials?

Curing diseases requires new drugs. Getting those new drugs approved by regulators requires data from successful clinical trials. Those trials depend on patients, and right now getting those patients is a challenge for many sponsor companies. According to research performed on recruitment, 85 percent of trials are delayed due to enrollment issues and more than 30 percent of total trial time is spent simply recruiting patients. Those issues are present...
In the News

Minority Participation in Clinical Trials can Help Everyone Fight Alzheimer’s

November 6, 2017
Growing up as an African-American in the South over 75 years ago, my family didn’t have the access to medical care we do today. One event from my childhood changed my life.  My mother went to the doctor’s office. She was quite ill and needed help. The doctor said she had to wait to be seen until after all of the white patients were assisted. It was at that moment...
Press Releases

Global Alzheimer’s Platform (GAP) Foundation Unites 58 of the World’s Leading Research Sites With Goal of Doubling Clinical Trial Participation in USA

November 1, 2017
More than Half of All National Clinical Trials in Alzheimer’s Take Place at GAP Networked Sites Kansas City Pilot Program Increased Volunteer Trial Participation by 292% WASHINGTON, D.C. (November 1, 2017) – Alzheimer’s disease affects more than 5.4 million Americans and costs taxpayers at least $153 billion dollars per year in Medicare and Medicaid expenses alone. It is projected that 14 million people in the U.S. will be afflicted with Alzheimer’s...
In the News

Patient Advocacy Groups Welcome 40% Increase in Alzheimer’s NIH Research Funds Authorized by Congress

May 9, 2017
The U.S. Congress last week authorized an additional 40 percent in funds for Alzheimer’s disease (AD) research, boosting the fiscal 2017 total by $400 million to nearly $1.4 billion as part of a $2 billion year-over-year increase for the National Institutes of Health (NIH). The final package won praise from the nonprofit Global Alzheimer’s Platform Foundation (GAP), a Washington- based entity launched in 2015 by UsAgainstAlzheimer’s and the Global CEO Initiative (CEOi) on...
Press Releases

Global Alzheimer’s Platform Foundation Supports $400 Million Congressional Increase for Alzheimer’s Research Funding

May 4, 2017
Increase is Part of National Institutes of Health (NIH) $2 Billion Funding Boost Bipartisan Support is Good Newsfor 5.5 Million Americans Living with Alzheimer’s and their Caregivers WASHINGTON, D.C. (May 4, 2017) – The Global Alzheimer’s Platform Foundation, a nonprofit organization dedicated to expediting Alzheimer’s clinical trials, applauds today’s $400 million Congressional increase in Alzheimer’s research funding. Under the bipartisan vote, the National Institutes of Health (NIH) will receive a $2 billion boost in fiscal year 2017, as...
In the News

Hope to Prevent Alzheimer’s? Grab the Olive Oil and Hop on a Treadmill

November 26, 2016
Ann Poehler’s strides quicken on the treadmill. Her feet pound. Her heart races from 150 to 160 beats per minute and more. A plastic tube jutting from the Prairie Village woman’s mouth feeds carbon dioxide levels to a computer here inside the University of Kansas Alzheimer’s Disease Center. The computer records every respiration while an exercise physiologist coaches her to push harder. “Can you hang in there like for 15 more...
Press Releases

Global Alzheimer’s Platform Foundation Appoints Pascale Witz to Board of Directors

September 15, 2016
Pascale Witz brings two decades of healthcare leadership experience to GAP Board WASHINGTON, D.C. (Sep. 15, 2016) – Global Alzheimer's Platform Foundation, Inc. (GAP), a nonprofit organization dedicated to reducing the duration, cost and risk of Alzheimer’s clinical trials, today announced the appointment of Pascale Witz to its Board of Directors. In this role, Pascale will provide counsel based on her vast experience working as a healthcare executive with leading healthcare companies. The three-year...
In the News

National Survey Finds that a Majority of Americans Would Consider Participating in an Alzheimer’s Clinical Trial

August 1, 2016
A recent online survey conducted by Harris Poll found that nearly 60% of Americans are definitely willing or willing to consider taking part in a clinical trial for Alzheimer’s. This promising statistic is good news for researchers; however, obtaining qualified trial participants has been one of the greatest challenges in getting clinical trials off the ground. To address this, the Global Alzheimer’s Platform Foundation commissioned a survey to examine Americans’...
Press Releases

Global Alzheimer’s Platform Foundation Announces GAP-Net

July 28, 2016
First?of?its?Kind Network of Clinical Trial Sites Quickens Timeline and Quality of Alzheimer’s Clinical Trials WASHINGTON, D.C. (July 28, 2016) – The Global Alzheimer’s Platform Foundation (GAP) announced the launch of GAP?Net, a first?of?its?kind network of clinical trial sites collaboratively working to streamline clinical research and drug development for Alzheimer’s disease. GAP?Net currently has 11 leading academic and private commercial research site partners. The network looks to add a minimum of 20 more sites by...
Press Releases

Global Alzheimer’s Platform Foundation Appoints Dr. Kate Zhong as Chief Strategy Officer

July 27, 2016
Dr. Zhong Brings More Than 20 Years of Experience to Organization’s New Role WASHINGTON, D.C. (July 27, 2016) – Global Alzheimer's Platform Foundation (GAP), a nonprofit organization dedicated to reducing the time, cost and risk of Alzheimer’s clinical trials, today announced the appointment of Dr. Kate Zhong to the new position of Chief Strategy Officer (CSO). In this role, Dr. Zhong will lead strategic development advancing GAP’s efforts to disrupt the inefficient clinical...
Press Releases

Majority Of Americans Would Consider Participating In An Alzheimer’s Clinical Trial. So, Why Are Enrollment Numbers So Low?

July 18, 2016
Global Alzheimer’s Platform (GAP) Foundation is promoting innovative and easier?to?use clinical trial participation tools, including the Brain Health Registry WASHINGTON, D.C. (July 18, 2016) – In a first?ever poll conducted online by Harris Poll on behalf of the Global Alzheimer’s Platform (GAP) Foundation, nearly 60% of Americans report they are definitely willing or would consider participating in Alzheimer’s disease clinical trials, but participation rates show that less than 10% are actually...